TY - JOUR
T1 - Bevacizumab-based first-line chemotherapy in elderly patients with metastatic colorectal cancer
T2 - An individual patient data based meta-analysis
AU - Koch, Christine
AU - Schwing, Anna M.
AU - Herrmann, Eva
AU - Borner, Markus
AU - Diaz-Rubio, Eduardo
AU - Dotan, Efrat
AU - Feliu, Jaime
AU - Okita, Natsuko
AU - Souglakos, John
AU - Arkenau, Hendrik T.
AU - Porschen, Rainer
AU - Koopman, Miriam
AU - Punt, Cornelis J.A.
AU - de Gramont, Aimery
AU - Tournigand, Christophe
AU - Zeuzem, Stefan
AU - Trojan, Joerg
N1 - Funding Information:
Editorial support was provided by Miller Medical Communications Ltd, funded by Roche Pharma, Germany.
Publisher Copyright:
© Koch et al.
PY - 2018/2/13
Y1 - 2018/2/13
N2 - Background: The aim of this meta-analysis was to evaluate efficacy and safety of first-line chemotherapy with or without a monoclonal antibody in elderly patients ( ≥ 70 years) with metastatic colorectal cancer (mCRC), since they are frequently underrepresented in clinical trials. Results: Individual data from 10 studies were included. From a total of 3271 patients, 604 patients (18%) were ≥ 70 years (median 73 years, range 70-88). Of these, 335 patients were treated with a bevacizumab-based first-line regimen and 265 were treated with chemotherapy only. The median PFS was 8.2 vs. 6.5 months and the median OS was 16.7 vs. 13.0 months in patients treated with and without bevacizumab, respectively. The safety profile of bevacizumab in combination with first-line chemotherapy did not differ from published clinical trials. Materials and Methods: PubMed and Cochrane Library searches were performed on 29 April 2013 and studies published to this date were included. Authors were contacted to request progression-free survival (PFS), overall survival (OS) data, patient data on treatment regimens, age, sex and potential signs of toxicity in patients ≥ 70 years of age. Conclusions: This meta-analysis suggests that the addition of bevacizumab to standard first-line chemotherapy improves clinical outcome in elderly patients with mCRC and is well tolerated.
AB - Background: The aim of this meta-analysis was to evaluate efficacy and safety of first-line chemotherapy with or without a monoclonal antibody in elderly patients ( ≥ 70 years) with metastatic colorectal cancer (mCRC), since they are frequently underrepresented in clinical trials. Results: Individual data from 10 studies were included. From a total of 3271 patients, 604 patients (18%) were ≥ 70 years (median 73 years, range 70-88). Of these, 335 patients were treated with a bevacizumab-based first-line regimen and 265 were treated with chemotherapy only. The median PFS was 8.2 vs. 6.5 months and the median OS was 16.7 vs. 13.0 months in patients treated with and without bevacizumab, respectively. The safety profile of bevacizumab in combination with first-line chemotherapy did not differ from published clinical trials. Materials and Methods: PubMed and Cochrane Library searches were performed on 29 April 2013 and studies published to this date were included. Authors were contacted to request progression-free survival (PFS), overall survival (OS) data, patient data on treatment regimens, age, sex and potential signs of toxicity in patients ≥ 70 years of age. Conclusions: This meta-analysis suggests that the addition of bevacizumab to standard first-line chemotherapy improves clinical outcome in elderly patients with mCRC and is well tolerated.
KW - Bevacizumab
KW - Elderly
KW - First-line chemotherapy
KW - Metastatic colorectal cancer
UR - http://www.scopus.com/inward/record.url?scp=85041957771&partnerID=8YFLogxK
U2 - 10.18632/oncotarget.23475
DO - 10.18632/oncotarget.23475
M3 - Article
C2 - 29535805
AN - SCOPUS:85041957771
SN - 1949-2553
VL - 9
SP - 10272
EP - 10283
JO - Oncotarget
JF - Oncotarget
IS - 12
ER -